These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35722277)

  • 21. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors.
    Bauer C; Duewell P; Lehr HA; Endres S; Schnurr M
    Dig Dis; 2012; 30 Suppl 1():82-90. PubMed ID: 23075874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals.
    Shenoy AR; Wellington DA; Kumar P; Kassa H; Booth CJ; Cresswell P; MacMicking JD
    Science; 2012 Apr; 336(6080):481-5. PubMed ID: 22461501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NADPH Oxidase and Guanylate Binding Protein 5 Restrict Survival of Avirulent Type III Strains of Toxoplasma gondii in Naive Macrophages.
    Matta SK; Patten K; Wang Q; Kim BH; MacMicking JD; Sibley LD
    mBio; 2018 Aug; 9(4):. PubMed ID: 30154263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
    Perera AP; Kunde D; Eri R
    Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.
    Gironella M; Iovanna JL; Sans M; Gil F; Peñalva M; Closa D; Miquel R; Piqué JM; Panés J
    Gut; 2005 Sep; 54(9):1244-53. PubMed ID: 15870231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of WT161 as a Potent Agent for the Treatment of Colitis by Targeting the Nucleotide-Binding Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome.
    Long X; Yu X; Gong P; Wang X; Tian L
    Front Pharmacol; 2022; 13():780179. PubMed ID: 35330829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease.
    Brenna Ø; Bruland T; Furnes MW; Granlund Av; Drozdov I; Emgård J; Brønstad G; Kidd M; Sandvik AK; Gustafsson BI
    Scand J Gastroenterol; 2015; 50(10):1241-52. PubMed ID: 25979109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies.
    Dionne S; Hiscott J; D'Agata I; Duhaime A; Seidman EG
    Dig Dis Sci; 1997 Jul; 42(7):1557-66. PubMed ID: 9246063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease.
    Zhong W; Kolls JK; Chen H; McAllister F; Oliver PD; Zhang Z
    Front Biosci; 2008 Jan; 13():1654-64. PubMed ID: 17981657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease.
    Christophi GP; Rong R; Holtzapple PG; Massa PT; Landas SK
    Inflamm Bowel Dis; 2012 Dec; 18(12):2342-56. PubMed ID: 22467146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of the selenoprotein S (SELS) gene -105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation.
    Seiderer J; Dambacher J; Kühnlein B; Pfennig S; Konrad A; Török HP; Haller D; Göke B; Ochsenkühn T; Lohse P; Brand S
    Tissue Antigens; 2007 Sep; 70(3):238-46. PubMed ID: 17661913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of the "A Disintegrin And Metalloprotease" 19 (ADAM19), a sheddase for TNF-α in the mucosa of patients with inflammatory bowel diseases.
    Franzè E; Caruso R; Stolfi C; Sarra M; Cupi ML; Ascolani M; Sedda S; Antenucci C; Ruffa A; Caprioli F; MacDonald TT; Pallone F; Monteleone G
    Inflamm Bowel Dis; 2013 Mar; 19(3):501-11. PubMed ID: 23429442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease.
    Song Y; Zhao Y; Ma Y; Wang Z; Rong L; Wang B; Zhang N
    Cytokine Growth Factor Rev; 2021 Aug; 60():61-75. PubMed ID: 33773897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.
    Rafa H; Saoula H; Belkhelfa M; Medjeber O; Soufli I; Toumi R; de Launoit Y; Moralès O; Nakmouche M; Delhem N; Touil-Boukoffa C
    J Interferon Cytokine Res; 2013 Jul; 33(7):355-68. PubMed ID: 23472658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trimethylamine N-oxide prime NLRP3 inflammasome via inhibiting ATG16L1-induced autophagy in colonic epithelial cells.
    Yue C; Yang X; Li J; Chen X; Zhao X; Chen Y; Wen Y
    Biochem Biophys Res Commun; 2017 Aug; 490(2):541-551. PubMed ID: 28629999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-κB signaling.
    Chen X; Liu G; Yuan Y; Wu G; Wang S; Yuan L
    Cell Death Dis; 2019 Dec; 10(12):906. PubMed ID: 31787755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease.
    Wehkamp J; Fellermann K; Herrlinger KR; Baxmann S; Schmidt K; Schwind B; Duchrow M; Wohlschläger C; Feller AC; Stange EF
    Eur J Gastroenterol Hepatol; 2002 Jul; 14(7):745-52. PubMed ID: 12169983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokines in inflammatory bowel disease.
    Kmieć Z
    Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased expression of IL-16 in inflammatory bowel disease.
    Seegert D; Rosenstiel P; Pfahler H; Pfefferkorn P; Nikolaus S; Schreiber S
    Gut; 2001 Mar; 48(3):326-32. PubMed ID: 11171821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in cytokine gene expression profile in colon mucosa of Inflammatory Bowel Disease patients on different therapeutic regimens.
    Velikova T; Kyurkchiev D; Spassova Z; Karakolev I; Ivanova-Todorova E; Altankova I; Stanilova S
    Cytokine; 2017 Apr; 92():12-19. PubMed ID: 28088612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.